2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Jump to: View All • a b c d e f g h i j k l m [n] o p q r s t u v w x y z

Abstract Number: 382

Nailfold Capillary Changes in the Adult Newly Onset-Dermatomyositis: A Prospective Cohort Study
Abstract Number: 374

Nailfold Microangiopathy in Dermatomyositis and Systemic Sclerosis: What Is Different?
Abstract Number: 2157

Nationwide Estimated Prevalence of SLE: United States Population-Based Study, 2001-2011
Abstract Number: 1085

Natural Gingerols Inhibit Neutrophil Extracellular Trap Release Elicited By Lupus Autoantibodies
Abstract Number: 2441

Needs and Barriers to Pregnancy Counselling in Women with SLE
Abstract Number: 2419

Needs Assessment and Implementation of a Reproductive Health Intention Screen for Women with Systemic Rheumatic Diseases
Abstract Number: 182

Needs Assessment of a Structured Program for Fellows As Teachers: Rheumatology Program Directors’ Perspective
Abstract Number: 183

Needs Assessment of a Structured Teaching Program for Fellows As Teachers: Rheumatology Fellows’ Perspective
Abstract Number: 2361

Needs, Experiences and Views of People with Rheumatic and Musculoskeletal Diseases about Self-Management Mobile Health Apps: Results of a Mixed Methods Approach
Abstract Number: 701

Network Meta-Analysis of Targeted Immunomodulators in the Treatment of Psoriatic Arthritis Patients without Prior Biologic Treatment
Abstract Number: 457

Neuropathic Pain in Patients with Knee Osteoarthritis (Preliminary Report)
Abstract Number: 2117

Neuropsychiatric Systemic Lupus Erythematosus Is Attenuated By Sphingosine-1-Phosphate Receptor Modulation
Abstract Number: 935

Neuropsychiatric Systemic Lupus Erythematosus Is Dependent on Lipocalin-2
Abstract Number: 2095

Neutralizing CXCL13 Attenuates Neuropsychiatric Disease in Lupus-Prone Mice
Abstract Number: 996

Neutralizing Effect of Anti-Infliximab Antibodies on Infliximab-Stimulated Human Coronary Artery Endothelial Cells
Abstract Number: 1456

Neutrophil Activation Is Associated with Disease Activity and Predicts Development of Erosive Disease and Extra Articular Manifestations in Rheumatoid Arthritis
Abstract Number: 2116

Neutrophil Extracellular Trap Formation Is Dependent on Disease Activity in Systemic Lupus Erythematosus: Determination Using a Flow Cytometry-Based Assay
Abstract Number: 766

Neutrophil Extracellular Traps Are a Source of Extracellular High Mobility Group Box-1: Association with Clinical and Histopathological Features in Patients with Lupus Nephritis
Abstract Number: 1003

Neutrophil Response to Ultraviolet Light in Normal and Lupus Conditions
Abstract Number: 2775

Neutrophil to Lymphocyte Ratio Predicts Glucocorticoid Resistance in Polymyalgia Rheumatica
Abstract Number: 1916

Neutrophil-to-Lymphocyte Ratio Prospectively Predicts the Development of Rheumatic Immune-Related Adverse Events from PD-1 Inhibitor Therapy
Abstract Number: 923

Neutrophils from Children with Systemic JIA Exhibit Persistent Proinflammatory Activation Despite Long-Standing Clinically Inactive Disease
Abstract Number: L01

New Cardiovascular Events in Patients with Gout Treated with Xanthine-Oxidase Inhibitors: An Inception Cohort Analysis
Abstract Number: 981

New Consensus on an Updated Core Domain Set for Clinical Trials in Juvenile Idiopathic Arthritis
Abstract Number: 845

New Insights in Lupus Dermatitis: Differential Regulation and Roles of Tissue-Resident Dendritic Cell Subsets in the Pathogenesis of Autoimmune Skin Inflammation
Abstract Number: 2916

New JADAS10- and cJADAS10-Based Cutoffs for Juvenile Idiopathic Arthritis Disease Activity States: Validation in a Multinational Dataset of 4830 Patients
Abstract Number: 1795

New Major Organ Involvement Is Lower in Young Male Behçet’s Patients Compared to Retrospective Series: Five-Year Results of a Prospective Cohort
Abstract Number: 2407

New Onset of Uveitis in Non-Methotrexate Group, Methotrexate Group and Etanercept Group in Juvenile Idiopathic Arthritis
Abstract Number: 699

New Onset/Recurrence of Inflammatory Arthralgia/Spondyloarthritis in Patients Treated with Vedolizumab for Intestinal Bowel Disease
Abstract Number: 1464

Newer Generation Cyclic Citrullinated Peptide (CCP) 3.1 Assay in the Diagnosis of Rheumatoid Arthritis
Abstract Number: 2014

Next Generation Sequencing Analysis of Familial Haemophagocytic Lymphohistiocytosis (HLH) Related Genes in Macrophage Activation Syndrome (MAS) and Secondary HLH (sHLH)
Abstract Number: 2851

NF-Κappa b Signaling in the Myeloid Cell Lineage Drives the Pathogenesis of Immune-Mediated Nephritis
Abstract Number: 2459

Nivolumab-Induced Synovial Tissue T Cell Infiltration, Sustained PD1 Occupancy and Resolution of Severe Synovitis with Infliximab Therapy
Abstract Number: 1552

No Effect of Concomitant Glucocorticoid Therapy on Efficacy and Safety of Tocilizumab Monotherapy Found in Rheumatoid Arthritis Clinical Trials
Abstract Number: 340

No Improvement in Time to Biopsy and Therapy in Lupus Nephritis Patients over Two Decades
Abstract Number: 831

No More HCV RNA in Serum and Cryoprecipitate in Patients with Persisting HCV-Cryoglobulinemia Vasculitis after Daa-Induced Sustained Virological Response
Abstract Number: 814

NON Diffuse SSc, Peripheral Neuropathy, Concomitant Sjogren Syndrome and ANTI-RNA Polymerase III Represent Risk Factors for the Higher Frequency of Cancer in a Large Single Cohort of Patients with Systemic Sclerosis
Abstract Number: 1813

Non-Aphthous Beginning As an Independent Risk Factor for the Course of Behçet’s Disease
Abstract Number: 2238

Non-Coding Urate-Associated Variants Function in a Conserved Lincrna Regulatory Domain That Alters MAF transcription
Abstract Number: 1160

Non-Elderly Adults Who Have Never Seen a Health-Care Provider for Chronic Joint Symptoms- Updated Results from National Health Interview Survey 2015
Abstract Number: 123

Non-Hematopoietic Derived TNF Drives Pulmonary Vasculopathy: A New Model of CTD-Associated Pulmonary Hypertension
Abstract Number: 508

Non-Invasive Evaluation of Left Atrial Pressure in Hispanic Patients with Rheumatoid Arthritis: A Case-Control Study
Abstract Number: 2933

Non-Invasive Tape Sampling Reveals RNA Gene Clusters in Cutaneous Lupus Erythematosus That Discriminate Affected from Unaffected and Healthy Volunteer Skin
Abstract Number: 220

Non-Medical Switch to Biosimilars: What Have We Learned?
Abstract Number: 1069

Non-Receptor Protein Tyrosine Phosphatase 14 (PTPN14) Promotes YAP-Dependent Tgfbeta Signaling in RA FLS
Abstract Number: 567

Non-Surgical Periodontal Therapy Plus Short-Term Antibiotic Treatment May Improve Clinical Disease Activity: A Pilot Study in Difficult to Treat Rheumatoid Arthritis
Abstract Number: 682

Nonsteroidal Anti-Inflammatory Drug Use and Hypertension in Ankylosing Spondylitis
Abstract Number: 2601

Nonsteroidal Anti-Inflammatory Drugs Attenuate Active Inflammatory Sacroiliac Joint Lesions in Patients with Early Axial Spondyloarthritis
Abstract Number: 2982

Normal Mortality of the Cobra Early Rheumatoid Arthritis Trial Cohort after 23 Years Follow up
Abstract Number: 2626

Normalization of CRP Levels and Clinical Response to Ixekizumab in Patients with Psoriatic Arthritis: Results from the Spirit Studies
Abstract Number: 2627

Not All Clinical Responders in SLE Are Equal: Comparison of Subcutaneous Belimumab + Standard of Care Responders to Placebo + Standard of Care Responders
Abstract Number: 2249

Not Just a Swollen Big Toe: Increasing All-Cause Hospitalizations in Patients with Gout in the United States: 1993–2014
Abstract Number: 43

Novel Anti-Malarial Drug Derivative Inhibited Anti-Citrullinated Protein/Peptide Antibodies and Rheumatoid Factors Production in Dnaseii/Ifnr Double Knock out Mice
Abstract Number: 2682

Novel Antibody Against Commensal Bacterial Antigen in Prediction of the Response of Rituximab in Systemic Lupus Erythematosus
Abstract Number: 2296

Novel Classification of Idiopathic Inflammatory Myopathies Based on Distinctive Features and Autoantibodies: Analysis of 67 Korean Patients
Abstract Number: 2208

Novel Fluorescence Optical Imaging Scoring System of Inflammation in the Hand and Wrist Is in Patients with Rheumatoid Arthritis – Agreement with Ultrasonography and Sensitivity to Change
Abstract Number: 2020

Novel Serum Biomarkers Monitor Disease Progression and Response to Change in Corticosteroid Therapy in Children with Juvenile Dermatomyositis
Abstract Number: 132

Novel Therapeutic Peptides Which Target CD206 Inhibit Macrophage Dependent Fibroblast Activation in Scleroderma
Abstract Number: 2098

NRF2 Downregulates Inflammation and Protects Against Autoimmune Lung Disease in Experimental Lupus
Abstract Number: 977

Nurse Led Safe Switching from Original Reference Product Infliximab to Biosimalar in Patients with Juvenile Idiopathic Arthritis and Uveitis – a Single Centre Experience Including Baseline and Post Switch Infliximab Levels and Antibodies

Jump to: View All • a b c d e f g h i j k l m [n] o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].